Immutep targets 2H 2027 start for efti trials in PD-L1-negative head and neck cancer, soft tissue sarcoma
IMMP•Immutep outlines revised efti development plan
Immutep reset efti’s registration strategy, prioritizing head and neck cancer in PD-L1-negative patients plus neoadjuvant soft tissue sarcoma.
No new trial results were presented; the plan relies on previously reported positive signals in those settings.
Development was redirected following TACTI-004’s early stop, with analysis pointing to manufacturing-related product differences as a likely driver.
Preparations began for new studies targeted to start in 2H 2027, subject to trial design, regulators, manufacturing, funding, partnering.
A new 200 L manufacturing run was contracted to return to the earlier product used in prior studies with more consistent immune activity.
